Skip to Content
Business Wire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zosano Pharma Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zosano Pharma Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zosano Pharma Corporation (“Zosano” or “the Company”) (NASDAQ: ZSAN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between February 13, 2017 and September 30, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before December 28, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Zosano’s clinical trials of Qtrypta observed differences in zolmitriptan exposures in subjects between different lots. Studies submitted to the FDA by the Company included patients suffering from unexpected high plasma concentrations of zolmitriptan. The FDA was likely to require additional studies before approving Qtrypta. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Zosano, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20201030005738/en/